Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-0015 in Advanced Solid Tumors
NCT06983743Phase 1Recruiting
- Sponsor
- Erasca
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERAS-0015 in solid tumor (2 arms), sponsored by Erasca. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 6 more. Started Jun 2025; status: recruiting.
02
Drugs
ERAS-0015
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06983743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983743.